Company Overview of Aduro BioTech, Inc.
Aduro BioTech, Inc., a clinical-stage biotechnology company, develops immunotherapy solutions for the treatment of cancer. The company develops a pipeline of new immunotherapies and immunotherapy combinations, including CRS-207, a solution based on Listeria platform to express the tumor-associated antigen mesothelin in patients with metastatic pancreatic cancer; and ADU-623, a clinical bivalent Listeria-based immunotherapy for patients with glioblastoma. It also develops ADU-214, a bivalent Listeria-based immunotherapy that targets mesothelin and EGFR mutations; ADU-741, a solution based on live-attenuated double-deleted immunotherapy platform for the treatment of prostate cancer; cyclic din...
626 Bancroft Way
Berkeley, CA 94710-2224
Founded in 2000
Key Executives for Aduro BioTech, Inc.
Vice President of Finance
Senior Vice President of Research & Development
Head of Molecular Biology
Compensation as of Fiscal Year 2014.
Aduro BioTech, Inc. Key Developments
Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer Immunotherapies
Oct 16 14
Aduro BioTech, Inc. announced that it has entered into its second agreement with Janssen Biotech, Inc., granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform. Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro will receive a $30 million up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817 million. In addition, Aduro is eligible to receive high single-digit to double-digit tiered royalties on worldwide net sales upon successful launch and commercialization. Under the agreement, Janssen will have exclusive rights to develop and commercialize LADD product candidates in lung cancer and will assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. Aduro may provide assistance in any of these areas upon request and will receive additional fees for these support activities. The transaction is subject to clearance by the US antitrust authorities under the Hart-Scott-Rodino Act and will become final as soon as such clearance has occurred.
Aduro BioTech, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014
Sep 9 14
Aduro BioTech, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.
Aduro BioTech, Inc. Presents at BIO-Europe 2014, Nov-03-2014
Sep 3 14
Aduro BioTech, Inc. Presents at BIO-Europe 2014, Nov-03-2014 . Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions